ライフサイエンスコーパス: fibrinogen receptor

1 ), requires outside-in signaling through the fibrinogen receptor.

2 sess normal levels of the alpha(IIb)/beta(3) fibrinogen receptor.

3 pon active plasmin, yet independent of known fibrinogen receptors.

4 e C-regulated pathway leads to inhibition of fibrinogen receptor activation on platelets adherent to

5 Thromboxane A2 (TxA2) generation, as well as fibrinogen receptor activation, are normal in the absenc

6 cating that PKCdelta has no role in platelet fibrinogen receptor activation.

7 hibition of both pathways leads to abolished fibrinogen receptor activation.

8 tribution of G(12/13) activation to platelet fibrinogen receptor activation.

9 ocyte chemoattractant protein-1, P-selectin, fibrinogen, receptor activator of nuclear factor-kappaB

10 nearly 250 analogues, which were assayed for fibrinogen receptor affinity and inhibition of platelet

11 n RGE-containing peptide and four nonpeptide fibrinogen receptor (alpha IIb beta 3) antagonists faile

12 Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 gen

13 ation on sulfhydryl exposure in the platelet fibrinogen receptor, alpha IIb beta 3.

14 specificity from the structurally homologous fibrinogen receptor, alpha IIb beta 3.

15 of a fibrin clot is mediated by the platelet fibrinogen receptor, alpha(IIb)beta(3).

16 de loop of the integrin beta3 subunit of the fibrinogen receptor, alphaIIb beta3 (GPIIb-IIIa).

17 oxide, fibrinogen binding, and activation of fibrinogen receptor alphaIIbbeta3, was observed in throm

18 AR1 and PAR4 agonists also activate platelet fibrinogen receptor (alphaIIbbeta3).

19 uded that both outside-in signaling from the fibrinogen receptor and inside-out signaling from the P2

20 ot dependent on either the FcgammaRII or the fibrinogen receptor and that appears to play a role in p

21 re, occurs in 1% to 2% of patients given the fibrinogen receptor antagonist abciximab, a chimeric Fab

22 yl-beta-alanine, 6d (L-767,679), is a potent fibrinogen receptor antagonist able to inhibit the ADP-i

23 L-738, 167), a potent, selective non-peptide fibrinogen receptor antagonist is reported.

24 ation of this prodrug strategy to the chiral fibrinogen receptor antagonist L-734,217 resulted in a p

25 structure-activity surrounding the prototype fibrinogen receptor antagonist RWJ-50042 (racemate of 1)

26 ition of 2-MeSADP-induced TxA2 generation by fibrinogen receptor antagonist was not rescued by co-sti

27 y of 4, a potent thienothiophene non-peptide fibrinogen receptor antagonist, are reported.

28 SC49992, a fibrinogen receptor antagonist, blocked ADP-induced plat

29 tivation with aspirin had no effect, but the fibrinogen receptor antagonist, GR144053F, inhibited pla

30 he active metabolite of SC-54684A, an orally fibrinogen receptor antagonist.

31 Most clinical trials with fibrinogen receptor antagonists (FRAs) have been associa

32 Fibrinogen receptor antagonists block the fibrinogen-pla

33 exes and human platelets pretreated with the fibrinogen receptor antagonists eptifibatide or abcixima

34 y potent nonpeptide 3-oxo-1,4-benzodiazepine fibrinogen receptor antagonists from a constrained, RGD-

35 A series of highly potent and specific fibrinogen receptor antagonists have been discovered and

36 ent, selective, orally active, peptide-based fibrinogen receptor antagonists with a long duration of

37 that insect salivary glands are a source of fibrinogen receptor antagonists.

38 ore spherical and extrude pseudopodia, their fibrinogen receptors are activated, causing them to aggr

39 e had nonsignificantly greater wound-induced fibrinogen receptor binding than the other subjects.

40 wn, except that alpha IIb beta 3, a platelet fibrinogen receptor, binds to the gamma C HHLGGAKQAGDV40

41 Inhibition of the fibrinogen receptor CD11b/CD18 protects from all immune

42 cytic differentiation that forms part of the fibrinogen receptor complex, GPIIb/IIIa.

43 bilization, cytoskeletal reorganization, and fibrinogen receptor conformation.

44 Platelet activation marked by activated fibrinogen receptor correlated to the severity of PAH (r

45 characterized by shape change, induction of fibrinogen receptor expression and release of granular c

46 t of Integrelin, which inhibits the platelet fibrinogen receptor glycoprotein (GP) IIb/IIIa, on the f

47 Variabilin was a potent antagonist of the fibrinogen receptor glycoprotein IIb-IIIa (GPIIb-IIIa; a

48 limited the ability to maintain the platelet fibrinogen receptor, glycoprotein alpha(IIb)/beta(3), in

49 , results from abnormalities in the platelet fibrinogen receptor, GP(IIb)-IIIa (integrin alpha(IIb)be

50 cy because of the lack or dysfunction of the fibrinogen receptor GPIIb/IIIa (integrin alphaIIbbeta3),

51 ough intravenously administered antiplatelet fibrinogen receptor (GPIIb/IIIa) antagonists have become

52 for GPIb differs from that reported for the fibrinogen receptor, GPIIb-IIIa, and could have profound

53 Activation of the fibrinogen receptor integrin alpha(IIb)beta(3) in respon

54 The human blood platelet fibrinogen receptor, integrin alphaIIbbeta3 (glycoprotei

55 protein that binds to the alpha(IIb)beta(3) fibrinogen receptor, interacts exclusively with activate

56 Integrin alpha(IIb)beta(3), a platelet fibrinogen receptor, is critically involved in thrombosi

57 Because alpha IIb beta 3, the platelet fibrinogen receptor, is required for normal hemostasis,

58 alphaIIbbeta3 (or GPIIb/IIIa), the platelet fibrinogen receptor, is unknown but may involve the bind

59 conclude that collagen-induced activation of fibrinogen receptor on adherent platelets through GPVI s

60 Integrin alphaIIbbeta3 functions as the fibrinogen receptor on platelets and mediates platelet a

61 clear whether collagen can directly activate fibrinogen receptors on the adherent platelets without a

62 ted that CD44 is the primary fibrin, but not fibrinogen, receptor on LS174T colon carcinomas.

63 elated, being inhibited by blocking platelet fibrinogen receptors or by preventing plasminogen bindin

64 ntegrin alpha v beta 3, a widely distributed fibrinogen receptor, recognizes the RGD572-574 motif in

65 Fibrinogen receptor subunits Itga2b (alphaIIb) and Itgb3

66 in the beta subunit of the alpha(IIb)beta(3) fibrinogen receptor, suggesting a mechanism for facilita

67 Integrin alpha(IIb)beta(3) is the fibrinogen receptor that mediates platelet adhesion and

68 ly activates the integrin alphaIIbbeta3 (the fibrinogen receptor), the PDI inhibitors were without ef

69 elet aggregation is mediated by the platelet fibrinogen receptor, the alpha IIb beta 3 integrin (glyc

70 ) is converted from an inactive to an active fibrinogen receptor, thereby mediating platelet aggregat